Clinical Trial

Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the safety, pharmacokinetic profile of Lisaftoclax (APG-2575) single agent and in combination with HHT/AZA in patients with relapsed/refractory AML and related myeloid malignancies.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2020-08-03; most recent amendment 2026-04-27.
Status change: Not Yet Recruiting → Recruiting 2020-10-15
Trial Details
NCT Number NCT04501120
Lead Sponsor Ascentage Pharma Group Inc.
Collaborators: Suzhou Yasheng Pharmaceutical Co., Ltd.
Conditions Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy
Enrollment 682 participants
Start Date 2020-09-28
Primary Completion 2028-09 (estimated)
Study Completion 2029-09 (estimated)
Updated on ClinicalTrials.gov 2026-04-29